Alliancebernstein L.P. decreased its stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 19.4% during the first quarter, Holdings Channel reports. The fund owned 77,100 shares of the biopharmaceutical company’s stock after selling 18,500 shares during the period. Alliancebernstein L.P.’s holdings in Inovio Pharmaceuticals were worth $510,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in INO. Vident Investment Advisory LLC boosted its stake in Inovio Pharmaceuticals by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 127,375 shares of the biopharmaceutical company’s stock valued at $843,000 after buying an additional 21,228 shares during the last quarter. American International Group Inc. boosted its stake in Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 2,695 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after buying an additional 11,765 shares during the last quarter. Stoneridge Investment Partners LLC boosted its stake in Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock valued at $1,684,000 after buying an additional 2,073 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Inovio Pharmaceuticals by 28.9% in the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after buying an additional 27,898 shares during the last quarter. Hedge funds and other institutional investors own 22.92% of the company’s stock.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) opened at 5.43 on Wednesday. Inovio Pharmaceuticals, Inc. has a one year low of $5.32 and a one year high of $9.95. The company has a 50 day moving average of $7.16 and a 200-day moving average of $6.84. The firm’s market cap is $405.22 million.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company’s revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.11) EPS. On average, equities research analysts predict that Inovio Pharmaceuticals, Inc. will post ($1.06) earnings per share for the current year.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/09/inovio-pharmaceuticals-inc-ino-stake-cut-by-alliancebernstein-l-p.html.

INO has been the subject of a number of recent analyst reports. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. Maxim Group set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Aegis reiterated a “buy” rating and set a $14.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Buy” and an average target price of $20.78.

In related news, Director David B. Weiner sold 8,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the completion of the sale, the director now owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.60% of the stock is currently owned by corporate insiders.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.